Fenofibrate


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Severe hypertriglyceridaemia
Adult: Standard micronised formulation: Initially, 67 mg tid or 200 mg once daily. May reduce to 67 mg bid, or increase to 67 mg 4 times daily, or 267 mg once daily according to response. Non-micronised formulation: Initially, 200-300 mg daily given in divided doses, then may be adjusted to 200-400 mg daily according to response. Improved bioavailability formulation: 40-160 mg once daily.

Oral
Mixed hyperlipidaemia
Adult: In patients at high CV risk in addition to a statin, or when a statin is contraindicated or not tolerated: Standard micronised formulation: Initially, 67 mg tid or 200 mg once daily. May reduce to 67 mg bid or increase to 67 mg 4 times daily or 267 mg once daily according to response. Non-micronised formulation: Initially, 200-300 mg daily given in divided doses, then may be adjusted to 200-400 mg daily according to response. Improved bioavailability formulation: 40-160 mg once daily.
Renal Impairment
GFR 30-59 mL/min/1.73 m2: Micronised formulation: 67 mg once daily. GFR <30 mL/min/1.73 m2: Contraindicated.
Hepatic Impairment
Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Active liver disease including primary biliary cirrhosis, unexplained persistent liver function abnormality, severe renal impairment (GFR <30 mL/min/1.73 m2), pre-existing gallbladder disease, pancreatitis (with the exception of acute pancreatitis due to severe hypertriglyceridaemia, known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen). Lactation.
Thận trọng
Patients with pre-disposing factors for myopathy and/or rhabdomyolysis (diabetes mellitus, personal or familial history of hereditary muscular disorders, hypoalbuminaemia, hypothyroidism, high alcohol intake, concomitant use with HMG-CoA reductase inhibitors), risk factors for venous thromboembolism. Mild to moderate renal impairment. Elderly. Pregnancy.
Phản ứng phụ
Significant: Cholelithiasis, agranulocytosis, thrombocytopenia, hypersensitivity, myopathy, rhabdomyolysis, pancreatitis, venous thromboembolism, elevated level of serum transaminase.
Blood and lymphatic system disorders: Decreased haemoglobin and leukocytes.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, flatulence.
Investigations: Increased serum creatinine, urea.
Musculoskeletal and connective tissue disorders: Diffuse myalgia, myopathy, muscular cramps and weakness.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, sinusitis, rhinitis.
Skin and subcutaneous tissue disorders: Rash, pruritus. urticaria, alopecia, photosensitivity.
MonitoringParameters
Monitor blood counts, lipid profile, LFT during therapy and periodically thereafter.
Tương tác
May increase risk of ciclosporin-induced nephrotoxicity. May increase risk of bleeding with oral anticoagulants (e.g. warfarin). Increased risk of myopathy and rhabdomyolysis with colchicine, HMG-CoA reductase inhibitors, and other fibrates. May enhance adverse effects of ezetimibe. May decrease absorption with bile acid sequestrants (except colesevelam).
Food Interaction
Increased rate of absorption with food.
Tác dụng
Description: Fenofibrate, a fibric acid derivative, reduces total plasma triglycerides by the activation of peroxisome proliferator-activated receptor-α (PPAR-α) and lipoprotein lipase, thereby leading to a reduced production of apoprotein CIII, and an increased synthesis of apoproteins AI and AII, and fatty acid transport protein. Thus, resulting to an increased VLDL catabolism, fatty acid oxidation, and elimination of atherogenic triglyceride-rich particles; as a result of a decrease in VLDL and LDL and an increase in HDL levels.
Pharmacokinetics:
Absorption: Readily absorbed from the gastrointestinal tract. Increased absorption with food except when given as choline salt. Bioavailability: Approx 81% (fenofibric acid). Time to peak plasma concentration: 2-8 hours.
Distribution: Widely distributed to most tissues. Plasma protein binding: Approx 99% mainly to plasma albumin (fenofibric acid).
Metabolism: Rapidly metabolised in the tissue and plasma via esterases to its active metabolite, fenofibric acid, then undergoes hepatic or renal inactivation via glucuronidation.
Excretion: Mainly via urine (approx 60% as metabolite); faeces (25%). Elimination half-life: Approx 20 hours (fenofibric acid).
Đặc tính

Chemical Structure Image
Fenofibrate

Source: National Center for Biotechnology Information. PubChem Database. Fenofibrate, CID=3339, https://pubchem.ncbi.nlm.nih.gov/compound/Fenofibrate (accessed on Jan. 20, 2020)

Bảo quản
Store between 15-30°C. Protect from moisture.
Phân loại MIMS
Phân loại ATC
C10AB05 - fenofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
References
Anon. Fenofibrate and Derivatives. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 22/03/2019.

Buckingham R (ed). Fenofibrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/03/2019.

Fenofibrate 200 mg Capsules (Teva UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 22/03/2019.

Fenofibrate Capsule (Torrent Pharmaceuticals Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 22/03/2019.

Fenofibrate Micro 267 mg Capsules (Teva UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 22/03/2019.

Joint Formulary Committee. Fenofibrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/03/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Fenofibrate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
XEM THÊM
LESS
  • Colestrim
  • Defechol
  • Dopathyl
  • Fegenor
  • Fenbrat 300
  • Fenofib
  • Fenofibrat 200
  • Fenofibrate DOMESCO
  • Fenoflex
  • Fenogetz
  • Fenohexal
  • Fenorate
  • Fenosup Lidose
  • Fernolid
  • Finabrat 100/300
  • Glifen
  • Glotyl
  • Hafenthyl
  • Lifemore
  • Lifibrat
  • Lipanthyl
  • Lipenthyl
  • Lipicard
  • Lipidcare
  • Lipidstop 200
  • Lipirate
  • Lipirate 160
  • Medothyl
  • pms-Lipisans
  • Philbisrol
  • Stanlip
  • TV.Fenofibrate
  • Vibrate
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in